

## Datasheet: AAI21AB

<b>Description:</b>	SHEEP ANTI BOVINE IgG1:Alk. Phos.
<b>Specificity:</b>	IgG1
<b>Format:</b>	Alk. Phos.
<b>Product Type:</b>	Polyclonal Antibody
<b>Isotype:</b>	Polyclonal IgG
<b>Quantity:</b>	0.5 mg

### Product Details

#### Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit [www.bio-rad-antibodies.com/protocols](http://www.bio-rad-antibodies.com/protocols).

	Yes	No	Not Determined	Suggested Dilution
ELISA	▪			1/1000 - 1/10000

Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using the appropriate negative/positive controls.

<b>Target Species</b>	Bovine
<b>Product Form</b>	Purified IgG conjugated to Alkaline Phosphatase - liquid
<b>Antiserum Preparation</b>	Antisera to bovine IgG1 were raised by repeated immunisation of sheep with highly purified antigen. Purified IgG prepared by affinity chromatography.
<b>Buffer Solution</b>	50mM HEPES, 0.1M NaCl, 1mM MgCl <sub>2</sub> , 0.1mM ZnCl <sub>2</sub>
<b>Preservative Stabilisers</b>	0.09% Sodium Azide (NaN <sub>3</sub> )
<b>Approx. Protein Concentrations</b>	IgG concentration 0.5mg/ml
<b>Immunogen</b>	Purified bovine IgG1.
<b>RRID</b>	AB_10730829
<b>Specificity</b>	<b>Sheep anti Bovine IgG1 polyclonal antibody</b> recognizes bovine IgG1.

No cross-reactivity with other bovine immunoglobulin classes is seen in immunoelectrophoresis. This product may cross-react with IgG1 from other species.

## References

1. Makepeace, B.L. *et al.* (2009) Immunisation with a multivalent, subunit vaccine reduced patent infection in a natural bovine model of Onchocerciasis during intense field exposure. [PLoS Negl. Trop. Dis. 3: e544.](#)
2. Colwell, D.D. *et al.* (2010) *Dicrocoelium dendriticum* in cattle from Cypress Hills, Canada: Humoral response and preliminary evaluation of an ELISA. [Vet Parasitol. 174: 162-5.](#)
3. Assad, A. *et al.* (2012) Immunophenotyping and characterization of BNP colostrum revealed pathogenic alloantibodies of IgG1 subclass with specificity to platelets, granulocytes and monocytes of all maturation stages. [Vet Immunol Immunopathol. 147: 25-34.](#)
4. Ploegaert, T.C. *et al.* (2010) Genetic variation of natural antibodies in milk of Dutch Holstein-Friesian cows. [J Dairy Sci. 93: 5467-73.](#)
5. Laviora, M.Á. *et al.* (2012) Avidity and subtyping of specific antibodies applied to the indirect assessment of heterologous protection against Foot-and-Mouth Disease Virus in cattle. [Vaccine. 30: 6845-50.](#)
6. Mansilla, F.C. *et al.* (2013) Dose-dependent immunogenicity of a soluble *Neospora caninum* tachyzoite-extract vaccine formulated with a soy lecithin/ $\beta$ -glucan adjuvant in cattle. [Vet Parasitol. pii: S0304-4017\(13\)00252-5.](#)
7. Panadero, R. *et al.* (2013) Effect of reinfestations on systemic immune responses in cattle naturally infested by *Hypoderma* sp. (Diptera: Oestridae). [Vet Parasitol. 193: 238-44.](#)
8. Van Meulder, F. *et al.* (2013) Granule exocytosis of granulysin and granzyme B as a potential key mechanism in vaccine-induced immunity in cattle against the nematode *Ostertagia ostertagi*. [Infect Immun. 81: 1798-809.](#)
9. Vordermeier, H.M. *et al.* (2003) Improved immunogenicity of DNA vaccination with mycobacterial HSP65 against bovine tuberculosis by protein boosting. [Vet Microbiol. 93: 349-59.](#)
10. Hansen, E.R. *et al.* (1989) Cutaneous T-cell lymphoma lesional epidermal cells activate autologous CD4+ T lymphocytes: involvement of both CD1+OKM5+ and CD1+OKM5- antigen-presenting cells. [J Invest Dermatol. 94: 485-91.](#)
11. Fiedor, C. *et al.* (2009) Evaluation of a milk ELISA for the serodiagnosis of *Dictyocaulus viviparus* in dairy cows. [Vet Parasitol. 166: 255-61.](#)
12. Almería, S. *et al.* (2009) Specific anti-*Neospora caninum* IgG1 and IgG2 antibody responses during gestation in naturally infected cattle and their relationship with gamma interferon production. [Vet Immunol Immunopathol. 130: 35-42.](#)
13. Trotta, M. *et al.* (2015) Simultaneous immunization of cattle with foot-and-mouth disease (FMD) and live anthrax vaccines do not interfere with FMD booster responses [Trials in Vaccinology. 4: 38-42.](#)
14. Prado, M.E. *et al.* (2011) Vaccination of dairy cows with recombinant *Streptococcus uberis* adhesion molecule induces antibodies that reduce adherence to and internalization of *S. uberis* into bovine mammary epithelial cells. [Vet Immunol Immunopathol. 141: 201-8.](#)
15. von Holtum, C. *et al.* (2008) Development and evaluation of a recombinant antigen-based ELISA for serodiagnosis of cattle lungworm. [Vet Parasitol. 151: 218-26.](#)

16. Van Neerven, R.J. *et al.* (2010) Milk derived antigen-specific antibodies, methods of preparation and uses thereof. [US Patent application no: US20100129377 A1](#)
17. Grit, G.H. *et al.* (2014) Evaluation of cellular and humoral systemic immune response against *Giardia duodenalis* infection in cattle. [Vet Parasitol. 202: 145-55.](#)
18. van Diemen, P.M. *et al.* (2007) Subunit vaccines based on intimin and Efa-1 polypeptides induce humoral immunity in cattle but do not protect against intestinal colonisation by enterohaemorrhagic *Escherichia coli* O157:H7 or O26:H-. [Vet Immunol Immunopathol. 116: 47-58.](#)
19. Riffault, S. *et al.* (2010) A new subunit vaccine based on nucleoprotein nanoparticles confers partial clinical and virological protection in calves against bovine respiratory syncytial virus. [Vaccine. 28: 3722-34.](#)
20. Vázquez, L. *et al.* (2012) Antigen-specific antibody isotypes, lymphocyte subsets and cytokine profiles in cattle naturally infested by *Hypoderma sp.* (Diptera: Oestridae). [Vet Parasitol. 184: 230-7.](#)
21. Patarroyo, J.H. *et al.* (2009) Immune response of bovines stimulated by synthetic vaccine SBm7462 against *Rhipicephalus (Boophilus) microplus*. [Vet Parasitol. 166: 333-9.](#)
22. Maree, F.F. *et al.* (2015) Intra-serotype SAT2 chimeric foot-and-mouth disease vaccine protects cattle against FMDV challenge. [Vaccine. 33 \(25\): 2909-16.](#)
23. Rybarczyk, J. *et al.* (2017) Effects of lactoferrin treatment on *Escherichia coli* O157:H7 rectal colonization in cattle. [Vet Microbiol. 202: 38-46.](#)
24. Bautista-Garfias, C.R. *et al.* (2015) Co-immunization of cattle with a vaccine against babesiosis and *Lactobacillus casei* increases specific IgG1 levels to *Babesia bovis* and *B. bigemina*. [Parasitol Int. 64 \(5\): 319-23.](#)
25. González-Hernández A *et al.* (2016) Host protective ASP-based vaccine against the parasitic nematode *Ostertagia ostertagi* triggers NK cell activation and mixed IgG1-IgG2 response. [Sci Rep. 6: 29496.](#)
26. Scott, K.A. *et al.* (2017) Evaluation of immune responses of stabilised SAT2 antigens of foot-and-mouth disease in cattle. [Vaccine. 35 \(40\): 5426-33.](#)
27. Sheng, Z.A. *et al.* (2019) Th2-related cytokines are associated with *Fasciola gigantica* infection and evasion in the natural host, swamp buffalo. [Vet Parasitol. 268: 73-80.](#)
28. Jiménez-Pelayo, L. *et al.* (2019) Early *Neospora caninum* infection dynamics in cattle after inoculation at mid-gestation with high (Nc-Spain7)- or low (Nc-Spain1H)-virulence isolates. [Vet Res. 50 \(1\): 72.](#)

---

**Storage**

Store at +4°C.  
DO NOT FREEZE.

This product should be stored undiluted.  
Should this product contain a precipitate we recommend microcentrifugation before use.

---

**Guarantee**

12 months from date of despatch

---

**Health And Safety Information**

Material Safety Datasheet documentation #10351 available at:  
10351: <https://www.bio-rad-antibodies.com/uploads/MSDS/10351.pdf>

---

**Regulatory**

For research purposes only

---

**North & South** Tel: +1 800 265 7376

**Worldwide**

Tel: +44 (0)1865 852 700

**Europe**

Tel: +49 (0) 89 8090 95 21

To

**America** Fax: +1 919 878 3751

Fax: +44 (0)1865 852 739

Fax: +49 (0) 89 8090 95 50

find a

Email: [antibody\\_sales\\_us@bio-rad.com](mailto:antibody_sales_us@bio-rad.com)

Email: [antibody\\_sales\\_uk@bio-rad.com](mailto:antibody_sales_uk@bio-rad.com)

Email: [antibody\\_sales\\_de@bio-rad.com](mailto:antibody_sales_de@bio-rad.com)

batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://bio-rad-antibodies.com/datasheets)

'M375006:201211'

**Printed on 22 Mar 2021**

---

© 2021 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)